The molecular basis underlying T cell specificity towards citrullinated epitopes presented by HLA-DR4.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 09 09 2023
accepted: 12 07 2024
medline: 24 7 2024
pubmed: 24 7 2024
entrez: 23 7 2024
Statut: epublish

Résumé

CD4

Identifiants

pubmed: 39043656
doi: 10.1038/s41467-024-50511-w
pii: 10.1038/s41467-024-50511-w
doi:

Substances chimiques

HLA-DR4 Antigen 0
Vimentin 0
Phosphopyruvate Hydratase EC 4.2.1.11
Epitopes, T-Lymphocyte 0
Citrulline 29VT07BGDA
Receptors, Antigen, T-Cell 0
Epitopes 0
Receptors, Antigen, T-Cell, alpha-beta 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6201

Informations de copyright

© 2024. The Author(s).

Références

Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. Nat. Rev. Immunol. 18, 325–339 (2018).
pubmed: 29292391 doi: 10.1038/nri.2017.143
Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205–1213 (1987).
pubmed: 2446635 doi: 10.1002/art.1780301102
Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).
pubmed: 22286218 pmcid: 3288335 doi: 10.1038/ng.1076
Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569–2582 (2013).
pubmed: 24190431 pmcid: 3832918 doi: 10.1084/jem.20131241
Huizinga, T. W. et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52, 3433–3438 (2005).
pubmed: 16255021 doi: 10.1002/art.21385
Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).
pubmed: 20872595 doi: 10.1002/art.27584
Berglin, E. et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 6, R303 (2004).
pubmed: 15225365 pmcid: 464874 doi: 10.1186/ar1187
Kroot E-JJA et al. The prognostic value of anti–cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43, 1831–1835 (2000).
doi: 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6
Van Gaalen, F. A. et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50, 2113–2121 (2004).
pubmed: 15248208 doi: 10.1002/art.20316
Vossenaar, E. R. & van Venrooij, W. J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther. 6, 107–111 (2004).
pubmed: 15142259 pmcid: 416453 doi: 10.1186/ar1184
van Venrooij, W. J., van Beers, J. J. & Pruijn, G. J. Anti-CCP antibodies: the past, the present and the future. Nat. Rev. Rheumatol. 7, 391–398 (2011).
pubmed: 21647203 doi: 10.1038/nrrheum.2011.76
Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet 34, 395–402 (2003).
pubmed: 12833157 doi: 10.1038/ng1206
Curran, A. M., Naik, P., Giles, J. T. & Darrah, E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 16, 301–315 (2020).
pubmed: 32341463 doi: 10.1038/s41584-020-0409-1
Ting, Y. T. et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J. Biol. Chem. 293, 3236–3251 (2018).
pubmed: 29317506 pmcid: 5836122 doi: 10.1074/jbc.RA117.001013
Hill, J. A. et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171, 538–541 (2003).
pubmed: 12847215 doi: 10.4049/jimmunol.171.2.538
Romero, V. et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci. Transl. Med. 5, 209ra150 (2013).
pubmed: 24174326 pmcid: 4032227 doi: 10.1126/scitranslmed.3006869
Darrah, E. & Andrade, F. Rheumatoid arthritis and citrullination. Curr. Opin. Rheumatol. 30, 72–78 (2018).
pubmed: 28937414 pmcid: 5848217 doi: 10.1097/BOR.0000000000000452
Derksen, V., Huizinga, T. W. J. & van der Woude, D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 39, 437–446 (2017).
pubmed: 28451788 pmcid: 5486798 doi: 10.1007/s00281-017-0627-z
Vossenaar, E. R. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6, R142–R150 (2004).
pubmed: 15059278 pmcid: 400433 doi: 10.1186/ar1149
Burkhardt, H. et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 35, 1643–1652 (2005).
pubmed: 15832289 doi: 10.1002/eji.200526000
Masson-Bessiere, C. et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J. Immunol. 166, 4177–4184 (2001).
pubmed: 11238669 doi: 10.4049/jimmunol.166.6.4177
Kinloch, A. et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res. Ther. 7, R1421–R1429 (2005).
pubmed: 16277695 pmcid: 1297593 doi: 10.1186/ar1845
James, E. A. et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66, 1712–1722 (2014).
pubmed: 24665079 pmcid: 4248674 doi: 10.1002/art.38637
Raza, K. et al. Detection of antibodies to citrullinated tenascin-C in patients with early synovitis is associated with the development of rheumatoid arthritis. RMD Open 2, e000318 (2016).
pubmed: 27933208 pmcid: 5133409 doi: 10.1136/rmdopen-2016-000318
Song, J. et al. Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis. JCI Insight 6, e145217 (2021).
pubmed: 33507879 pmcid: 8021118 doi: 10.1172/jci.insight.145217
Pieper, J. et al. Memory T cells specific to citrullinated α-enolase are enriched in the rheumatic joint. J. Autoimmun. 92, 47–56 (2018).
pubmed: 29853344 pmcid: 8259322 doi: 10.1016/j.jaut.2018.04.004
Snir, O. et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA–DRB1*0401–positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum. 63, 2873–2883 (2011).
pubmed: 21567378 pmcid: 3174345 doi: 10.1002/art.30445
Hill, J. A. et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205, 967–979 (2008).
pubmed: 18391064 pmcid: 2292232 doi: 10.1084/jem.20072051
Malmström, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17, 60–75 (2017).
pubmed: 27916980 doi: 10.1038/nri.2016.124
Lim, J. J. et al. The shared susceptibility epitope of HLA-DR4 binds citrullinated self-antigens and the TCR. Sci. Immunol. 6, eabe0896 (2021).
pubmed: 33863750 doi: 10.1126/sciimmunol.abe0896
Koning, F., Thomas, R., Rossjohn, J. & Toes, R. E. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Nat. Rev. Rheumatol. 11, 450–461 (2015).
pubmed: 25986717 doi: 10.1038/nrrheum.2015.59
Bang, H. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56, 2503–2511 (2007).
pubmed: 17665451 doi: 10.1002/art.22817
Mansour, H. E., Metwaly, K. M., Hassan, I. A., Elshamy, H. A. & Elbeblawy, M. M. Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clin. Med. Insights Arthritis Musculoskelet. Disord. 3, 33–42 (2010).
pubmed: 21124694 pmcid: 2989636 doi: 10.4137/CMAMD.S4827
Mahdi, H. et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat. Genet. 41, 1319–1324 (2009).
pubmed: 19898480 doi: 10.1038/ng.480
Goldbach-Mansky, R. et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2, 236–243 (2000).
pubmed: 11056669 pmcid: 17811 doi: 10.1186/ar93
Snir, O. et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann. Rheum. Dis. 68, 736–743 (2009).
pubmed: 18635594 doi: 10.1136/ard.2008.091355
Vander Cruyssen, B. et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res. Ther. 8, R122 (2006).
doi: 10.1186/ar2011
La Gruta, N. L. et al. Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J. Clin. Invest. 120, 1885–1894 (2010).
pubmed: 20440073 pmcid: 2877949 doi: 10.1172/JCI41538
Moon, J. J. et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27, 203–213 (2007).
pubmed: 17707129 pmcid: 2200089 doi: 10.1016/j.immuni.2007.07.007
Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169–200 (2015).
pubmed: 25493333 doi: 10.1146/annurev-immunol-032414-112334
Scally, S. W. et al. Molecular basis for increased susceptibility of Indigenous north Americans to seropositive rheumatoid arthritis. Ann. Rheum. Dis. 76, 1915–1923 (2017).
pubmed: 28801345 doi: 10.1136/annrheumdis-2017-211300
Sharma, R. K. et al. Biased TCR gene usage in citrullinated tenascin C specific T-cells in rheumatoid arthritis. Sci. Rep. 11, 24512 (2021).
pubmed: 34972837 pmcid: 8720095 doi: 10.1038/s41598-021-04291-8
Petersen, J. et al. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat. Struct. Mol. Biol. 21, 480–488 (2014).
pubmed: 24777060 doi: 10.1038/nsmb.2817
Pathiraja, V. et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4
pubmed: 25157096 doi: 10.2337/db14-0858
Tran, M. T. et al. T cell receptor recognition of hybrid insulin peptides bound to HLA-DQ8. Nat. Commun. 12, 5110 (2021).
pubmed: 34433824 pmcid: 8387461 doi: 10.1038/s41467-021-25404-x
Wegner, N. et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233, 34–54 (2010).
pubmed: 20192991 doi: 10.1111/j.0105-2896.2009.00850.x
van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 69, 1554–1561 (2010).
pubmed: 20448290 doi: 10.1136/ard.2009.124537
Ito, K. et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183, 2635–2644 (1996).
pubmed: 8676084 doi: 10.1084/jem.183.6.2635
Dash, P. et al. Paired analysis of TCRalpha and TCRbeta chains at the single-cell level in mice. J. Clin. Invest. 121, 288–295 (2011).
pubmed: 21135507 doi: 10.1172/JCI44752
Wang, X., Spandidos, A., Wang, H. & Seed, B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40, D1144–D1149 (2012).
pubmed: 22086960 doi: 10.1093/nar/gkr1013
Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503–W508 (2008).
pubmed: 18503082 pmcid: 2447746 doi: 10.1093/nar/gkn316
Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589–594 (2004).
pubmed: 15064769 doi: 10.1038/nbt957
Boulter, J. M. et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16, 707–711 (2003).
pubmed: 14560057 doi: 10.1093/protein/gzg087
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of coot. Acta Crystallogr D. Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002 pmcid: 2852313 doi: 10.1107/S0907444910007493
Adams, P. D. et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 213–221 (2010).
doi: 10.1107/S0907444909052925
Lefranc, M. P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27, 55–77 (2003).
pubmed: 12477501 doi: 10.1016/S0145-305X(02)00039-3

Auteurs

Tiing Jen Loh (TJ)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Jia Jia Lim (JJ)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Claerwen M Jones (CM)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Hien Thy Dao (HT)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Mai T Tran (MT)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Daniel G Baker (DG)

Janssen Research & Development, LLC, Horsham, Philadelphia, PA, USA.

Nicole L La Gruta (NL)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.

Hugh H Reid (HH)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia. hugh.reid@monash.edu.

Jamie Rossjohn (J)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia. jamie.rossjohn@monash.edu.
Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK. jamie.rossjohn@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH